We describe the results of a pilot clinical trial evaluating <sup>18</sup>F-radiohybrid(rh)PSMA-7.3-PET/MRI to detect occult adverse pathology among potential AS and FT candidates (NCT05852041).<h4>Methods</h4>We enrolled 20 men with low risk or favorable intermediate risk prostate cancer and Decipher score ≥ 0.45 diagnosed after an MRI-informed prostate biopsy. Here, FOLH1 is linked to prostate cancer.